Answers are grounded in this paper and cite their sources.
Personalized medicine takes into account individual patient factors that impact the efficacy of pharmaceutical therapies. Measuring the pharmacokinetic/toxicokinetic profile of a specific drug for each patient requires a cost‐effective, selective, robust and minimally invasive sensor. To that end, we have developed an electrochemical aptamer‐based indwelling sensor that achieves continuous, real‐time pharmacokinetic measurements of therapeutic drugs in living animals. Our preliminary experiments demonstrate that these sensors are selective to specific drug targets, durable and stable. We tested sensors selective to aminoglycosides, doxorubicin and cocaine, both in vitro and in vivo, and successfully measured fluctuating concentrations of therapeutics in real‐time. We carried out continuous measurements in Sprague‐Dawley rats ( n =6) treated intravenously with separate drugs to create metabolic profiles specific to each animal. We found that our sensors are sensitive to therapeutic doses of antibiotic aminoglycosides (including kanamycin and gentamicin), the antitumor chemotherapy drug doxorubicin, and cocaine. The sensors are stable for up to 6hrs (in vivo) and 12hrs (in vitro), with minimal signal decay over time. This work is a first step in achieving personalized medicine by tracking the pharmacokinetics of selective agents in vivo. Support or Funding Information This work was supported by the Keck Foundation (to TEK) and the Otis Williams Fellowship (to NAC).
No takes yet. Share an insight, caveat, or question.
Vieira et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: